What is Earlens Corporation?
Earlens Corporation operates at the intersection of audiology and advanced medical device engineering. The company is best known for its Earlens Contact Hearing Solution, a revolutionary, nonsurgical system that provides the broadest bandwidth in the industry. By utilizing a small lens to replicate the natural hearing process, the firm addresses the limitations of traditional acoustic hearing aids. Recognized as a TIME Top 100 Invention, Earlens has successfully navigated the regulatory environment, securing FDA clearance for its second-generation technology. The company's market position is defined by its commitment to high-fidelity sound quality and its ability to provide a superior, direct-activation alternative for patients suffering from hearing loss, effectively disrupting the conventional hearing aid market.
How much funding has Earlens Corporation raised?
Earlens Corporation has raised a total of $221M across 9 funding rounds:
Private Equity
$4.6M
Series A
$4.6M
Unspecified
$500K
Debt
$6.2M
Series B
$40M
Debt
$45M
Debt
$2M
Debt
$45M
Series C
$73M
Private Equity (2010): $4.6M, investors not publicly disclosed
Series A (2010): $4.6M, investors not publicly disclosed
Unspecified (2011): $500K, investors not publicly disclosed
Debt (2013): $6.2M, investors not publicly disclosed
Series B (2014): $40M backed by Aisling Capital, New Enterprise Associates, and Lightstone Ventures
Debt (2017): $45M with participation from CRG LP
Debt (2020): $2M led by PPP
Debt (2022): $45M supported by CRG
Series C (2022): $73M featuring RK Mellon, Cochlear, SightLine Partners, Vertex Healthcare, and Windham Venture Partners
Key Investors in Earlens Corporation
CRG LP
CR Group L.P. is a global investment firm providing flexible growth capital solutions, specializing in credit and equity investments across the life sciences and healthcare services sectors.
Cochlear
A global leader in implantable hearing solutions, Cochlear designs and manufactures advanced medical devices including cochlear and bone conduction implants.
SightLine Partners
Sightline Partners is an alternative investment manager focused on secondary buyouts and joint ventures within the high-growth medical technology and life sciences industries.
What's next for Earlens Corporation?
With the successful completion of this major enterprise-level funding round, Earlens Corporation is well-positioned to accelerate its commercial expansion and deepen its research and development initiatives. The strategic capital will likely be deployed to scale manufacturing capabilities, broaden market penetration, and support ongoing clinical studies to further validate the long-term efficacy of its contact hearing technology. As the company transitions into its next phase of growth, the focus will remain on enhancing patient outcomes and solidifying its competitive moat against traditional hearing aid manufacturers. The involvement of strategic partners and specialized healthcare investors suggests a clear roadmap toward sustained market leadership and potential future liquidity events within the medical device ecosystem.
See full Earlens Corporation company page
